Skip to main content Skip to section navigation Skip to footer
Achieve Life Sciences, Inc. IR Overview
Achieve Life Sciences Logo
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Careers
  • Products
    • Phase 3 ORCA-3 Trial
    • Phase 3 ORCA-2 Trial
    • Phase 2 ORCA-1 Trial
    • Phase 2 ORCA-V1 Trial
    • Expanded Access Policy
    • Resources
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
    • Overview
    • Management Team
    • Contacts
  • Financial Information
    • Overview
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jul 22, 2021 9:35 am EDT
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
Jun 29, 2021 5:30 am EDT
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
Jun 3, 2021 5:30 am EDT
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
Jun 2, 2021 5:30 am EDT
Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
May 27, 2021 4:05 pm EDT
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 25, 2021 8:30 am EDT
Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering
May 24, 2021 4:05 pm EDT
Achieve Life Sciences Announces Proposed Underwritten Public Offering
May 13, 2021 4:05 pm EDT
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
May 4, 2021 5:30 am EDT
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
Apr 22, 2021 5:30 am EDT
Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • …
  • Page 26
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

Jun 22, 2026
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
More News

© Copyright 2026 | Achieve Life Sciences, Inc., Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • References
  • twitter
  • linkedin